文献速递瓣膜病与结构性心脏病

中度混合性主动脉瓣病变的预后:与重度主动脉瓣狭窄及反流的比较

Outcomes of moderate mixed aortic valve stenosis and regurgitation.
PubMed 文献 · Eur Heart J · 2026-01-01

本研究纳入四个中心的1926例患者(中度混合性主动脉瓣病变527例、重度主动脉瓣反流413例、重度主动脉瓣狭窄986例),中位随访7.2年。调整临床和超声变量后,中度混合性主动脉瓣病变的10年生存率与重度主动脉瓣狭窄相似(62% vs 55%),但差于重度主动脉瓣反流(79%)。有症状或LVEF<50%的中度混合性主动脉瓣病变患者死亡率与相应情况的重度主动脉瓣狭窄相当,提示此类患者可从主动脉瓣置换术中获益。

要点

  • 中度混合性主动脉瓣病变的10年生存率(62%)与重度主动脉瓣狭窄(55%)相似,但低于重度主动脉瓣反流(79%)。
  • 有症状的中度混合性主动脉瓣病变患者调整后死亡率与有症状的重度主动脉瓣狭窄相当。
  • LVEF<50%的中度混合性主动脉瓣病变患者死亡率与LVEF<50%的重度主动脉瓣狭窄相当,提示应考虑主动脉瓣置换术。

核心结论

  • 中度混合性主动脉瓣病变患者若存在症状或LVEF<50%,其调整后死亡率与相似情况下的重度主动脉瓣狭窄患者相当,可能从主动脉瓣置换术中获益。

研究设计与样本

  • 多中心回顾性队列研究,纳入四个中心的1926例患者:中度混合性主动脉瓣病变527例、重度主动脉瓣反流413例、重度主动脉瓣狭窄986例。
  • 主要终点为全因死亡,中位随访7.2年(四分位距3.4-11.3年)。

主要发现

  • 随访期间共748例患者死亡。
  • 中度混合性主动脉瓣病变、重度主动脉瓣狭窄和重度主动脉瓣反流的10年生存率分别为62%、55%和79%(P < .001)。
  • 有症状的中度混合性主动脉瓣病变患者调整后死亡率与有症状的重度主动脉瓣狭窄相当;无症状的中度混合性主动脉瓣病变患者调整后死亡率与重度主动脉瓣反流(无论有无症状)相似。
  • LVEF<50%的中度混合性主动脉瓣病变患者调整后死亡率与LVEF<50%的重度主动脉瓣狭窄相当;LVEF≥50%的中度混合性主动脉瓣病变患者死亡率与重度主动脉瓣反流(无论有无左心室功能障碍)相似。

关键数值与推荐

  • 中度混合性主动脉瓣病变定义为中度主动脉瓣狭窄合并中度主动脉瓣反流。
  • 症状或LVEF<50%可作为中度混合性主动脉瓣病变患者考虑主动脉瓣置换术的指征。

临床怎么用

  • 对于中度混合性主动脉瓣病变患者,应评估症状和LVEF;若存在症状或LVEF<50%,可考虑主动脉瓣置换术。
  • 无症状且LVEF≥50%的中度混合性主动脉瓣病变患者预后与重度主动脉瓣反流相似,可能可采取保守观察策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: There are limited data on mortality in patients with moderate mixed aortic valve disease (MAVD), defined as the combination of moderate aortic stenosis (AS) and moderate aortic regurgitation (AR). Consequently, current guidelines lack specific recommendations for aortic valve replacement (AVR) in this population. This study aims to compare survival between moderate MAVD and isolated severe AS or severe AR, and to evaluate the impact of symptoms or left ventricular ejection fraction (LVEF) < 50%, as current criteria for AVR in severe AS or AR. METHODS: Overall, 1926 patients were included from four centers: 527 with moderate MAVD, 413 with severe AR, and 986 with severe AS. The primary endpoint was all-cause mortality. RESULTS: Over a median follow-up of 7.2 (interquartile range 3.4-11.3) years, 748 patients died. After adjusting for clinical and echocardiographic variables (including New York Heart Association [NYHA] class, LVEF < 50%, and AVR as time-dependent covariate), moderate MAVD patients showed 10-year survival similar to severe AS but worse than severe AR (62%, 55%, and 79%, respectively; P < .001). Symptomatic moderate MAVD patients showed adjusted mortality comparable to symptomatic severe AS, while asymptomatic moderate MAVD patients had adjusted mortality similar to severe AR (symptomatic and asymptomatic). Moderate MAVD patients with LVEF < 50% had adjusted mortality comparable to severe AS with LVEF < 50%, while those with LVEF ≥ 50% showed mortality similar to severe AR (regardless of left ventricular dysfunction). CONCLUSIONS: In moderate MAVD, the presence of symptoms or LVEF < 50% is associated with increased mortality, comparable to isolated severe AS under similar conditions. Therefore, patients with moderate MAVD should benefit from AVR in the presence of symptoms or left ventricular dysfunction.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Lopez Santi P, Bernard J, Chua A, et al. Outcomes of moderate mixed aortic valve stenosis and regurgitation. Eur Heart J. 2026. PMID: 41104570. doi:10.1093/eurheartj/ehaf791

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。